Introduction
toxicity, cancer, death, HCC
HEPATOCELLULAR CARCINOMA, CANCER, ADVERSE REACTIONS
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer around the world and the fourth leading cause of cancer-related death (Immune checkpoint inhibitors (ICIs), targeted therapy, and their combinations are now being investigated as first-line therapies for advanced HCC (Compared to monotherapy, combination therapy had a better prognosis and improved anti-tumor activity. Nonetheless, combination therapy tended to have higher incidence of adverse reactions, and this has been a major barrier to the widespread adoption of dual anti-PD-1/CTLA-4 therapy. Therefore, novel therapies are required to facilitate enhanced blockade of PD-1 and CTLA-4 with less toxicity in first-line treatment of HCC.Cadonilimab is a first-in-class, humanized, bispecific antibody targeting PD-1 and CTLA-4 simultaneously with Fc null design (